Civica Rx’s chief operating officer Ned McCoy is to step up as CEO, ahead of the company’s landmark manufacturing facility commencing operations in early 2024.

Hikma is looking for a new CEO after announcing that chief executive Siggi Olafsson will be leaving the company “to pursue other opportunities” on 24 June. In the meantime, executive chairman and former CEO Said Darwazah will take on his leadership responsibilities.

Formycon has become the latest firm to announce a new CEO, after similar moves at Orion and Strides. Meanwhile, Gedeon Richter has made management changes and a new director has joined Coherus.

Craig Burton is stepping up to become executive director of the US Association for Accessible Medicines’ Biosimilars Council, as Christine Simmon has moved on to become president and CEO of the Food and Drug Law Institute. At the same time, Burton has added oversight of strategic alliances to his existing policy role with the AAM.

Perrigo is set to welcome a new chief financial officer and corporate security head as it rounds up a fairly successful first quarter.

A major overhaul is in progress for Sawai’s Upsher-Smith business, after the Japanese parent company announced leadership changes and a “drastic restructuring” of the US unit in the wake of a significant impairment charge and a hefty annual operating loss that dragged down Sawai’s overall results.

Neuraxpharm has appointed Jörg Gärtner to lead its business in Switzerland, as the CNS specialist prepares to roll out its medical cannabis portfolio in the region.

Lupin has named a new head of compliance, emphasizing the importance of achieving the highest quality standards just weeks after the FDA notified the firm of observations following an inspection at its Indian facility in Tarapur.

Stada has announced the appointment of former Sandoz executive Christine Berndt as head of global development for specialty and biosimilar products, replacing Michael Mack.